Linezolid in Healthy Volunteers
Linezolid in Healthy Volunteers
Linezolid is the first synthetic antibiotic of oxazolidinone group that can inhibit bacterial
 protein synthesis. Previous studies have found that linezolid was an effective treatment for
 multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). In
 addition, the current dosage recommendation (1,200 mg/day) occasionally resulted in serious
 adverse events including bone marrow suppression and peripheral neuropathy.

 The objective study were determine the pharmacokinetics of oral linezolid 300 mg /day in
 healthy volunteers. This study conducted in six healthy volunteers. All subject received an
 oral linezolid 300 mg/day by directly observed treatment (DOT) at the same time each day for
 5 days. Blood samples were collected on day 5 at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and
 24 h post dosing. The separated plasma samples were evaluated by ultra-performance liquid
 chromatography (UPLC). All pharmacokinetic parameters were calculated.
Inclusion Criteria:

 -  Age 20 - 40

 -  BMI 19 - 24 kg/m2

 -  normal CLcr

 -  normal liver function

 Exclusion Criteria:

 -  Subject who pregnant

 -  Subject who have documented hypersensitivity to linezolid